177 related articles for article (PubMed ID: 21372165)
1. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
[TBL] [Abstract][Full Text] [Related]
2. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
3. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats.
Noguchi R; Yoshiji H; Ikenaka Y; Kaji K; Shirai Y; Aihara Y; Yamazaki M; Namisaki T; Kitade M; Yoshii J; Yanase K; Kawaratani H; Tsujimoto T; Fukui H
Int J Mol Med; 2010 Sep; 26(3):407-13. PubMed ID: 20664958
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
Tamaki Y; Nakade Y; Yamauchi T; Makino Y; Yokohama S; Okada M; Aso K; Kanamori H; Ohashi T; Sato K; Nakao H; Haneda M; Yoneda M
J Gastroenterol; 2013 Apr; 48(4):491-503. PubMed ID: 22886508
[TBL] [Abstract][Full Text] [Related]
5. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
[TBL] [Abstract][Full Text] [Related]
7. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Okura Y; Namisaki T; Moriya K; Kitade M; Takeda K; Kaji K; Noguchi R; Nishimura N; Seki K; Kawaratani H; Takaya H; Sato S; Sawada Y; Shimozato N; Furukawa M; Nakanishi K; Saikawa S; Kubo T; Asada K; Yoshiji H
Hepatol Res; 2017 Nov; 47(12):1317-1328. PubMed ID: 28029729
[TBL] [Abstract][Full Text] [Related]
9. Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development.
Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Shirai Y; Yoshii J; Yanase K; Fukui H
Int J Mol Med; 2011 Jul; 28(1):81-8. PubMed ID: 21455560
[TBL] [Abstract][Full Text] [Related]
10. Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Yoshiji H; Noguchi R; Namisaki T; Moriya K; Kitade M; Aihara Y; Douhara A; Kawaratani H; Nishimura N; Fukui H
J Gastroenterol; 2014 Oct; 49(10):1421-9. PubMed ID: 24197250
[TBL] [Abstract][Full Text] [Related]
11. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats.
Kitade M; Yoshiji H; Kojima H; Ikenaka Y; Noguchi R; Kaji K; Yoshii J; Yanase K; Namisaki T; Asada K; Yamazaki M; Tsujimoto T; Akahane T; Uemura M; Fukui H
Hepatology; 2006 Oct; 44(4):983-91. PubMed ID: 17006938
[TBL] [Abstract][Full Text] [Related]
12. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
Hepatology; 2001 Oct; 34(4 Pt 1):745-50. PubMed ID: 11584371
[TBL] [Abstract][Full Text] [Related]
14. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
Ibañez P; Solis N; Pizarro M; Aguayo G; Duarte I; Miquel JF; Accatino L; Arrese M
J Gastroenterol Hepatol; 2007 Jun; 22(6):846-51. PubMed ID: 17565640
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.
Kawaguchi K; Sakaida I; Tsuchiya M; Omori K; Takami T; Okita K
Biochem Biophys Res Commun; 2004 Feb; 315(1):187-95. PubMed ID: 15013444
[TBL] [Abstract][Full Text] [Related]
16. [Clinical utility of angiotensin II receptor antagonist].
Yokohama S; Nakamura K; Haneda M
Nihon Rinsho; 2006 Jun; 64(6):1152-6. PubMed ID: 16768124
[TBL] [Abstract][Full Text] [Related]
17. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
[TBL] [Abstract][Full Text] [Related]
18. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice.
Tomita K; Oike Y; Teratani T; Taguchi T; Noguchi M; Suzuki T; Mizutani A; Yokoyama H; Irie R; Sumimoto H; Takayanagi A; Miyashita K; Akao M; Tabata M; Tamiya G; Ohkura T; Hibi T
Hepatology; 2008 Aug; 48(2):458-73. PubMed ID: 18666257
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
